Hirai Fumihiko, Seto Takashi, Inamasu Eiko, Toyokawa Gouji, Yoshida Tsukihisa, Nosaki Kaname, Takenaka Tomoyoshi, Yamaguchi Masafumi, Takenoyama Mitsuhiro, Ichinose Yukito
Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
Anticancer Res. 2014 Oct;34(10):5743-7.
The aim of the present study was to retrospectively evaluate the role of S-1-based chemotherapy for patients with relapsed advanced thymic carcinoma (TC).
This study was a retrospective review of TC patients who had received S-1-based chemotherapy for patients with platinum- and antrathycline-failure TC. Patients received S-1 monotherapy or S-1/gemcitabine combination therapy, that were repeated until disease progression.
The patients consisted of 4 males and 4 females with a median age of 59 years (range=41-71); 2 with squamous cell carcinoma, 3 with undifferentiated carcinoma, 1 with poorly-differentiated neuroendocrine carcinoma and 2 not otherwise specified. Grade 3 or higher toxicity was only neutropenia (25.0%). No treatment-related death was observed. The response rate was 50.0% (95% confidence interval (CI)=21.5-78.5%). The median progression free-survival (PFS) and overall survival (OS) of S-1-based chemotherapy were 6.0 and 13.5 months, respectively.
S-1-based chemotherapy was found to be potentially useful for patients with relapsed TC.
本研究旨在回顾性评估基于S-1的化疗对复发晚期胸腺癌（TC）患者的作用。
本研究是一项对铂类和蒽环类药物治疗失败的TC患者接受基于S-1的化疗的回顾性分析。患者接受S-1单药治疗或S-1/吉西他滨联合治疗，重复给药直至疾病进展。
患者包括4名男性和4名女性，中位年龄59岁（范围=41-71岁）；2例为鳞状细胞癌，3例为未分化癌，1例为低分化神经内分泌癌，2例未另行明确分类。3级或更高毒性仅为中性粒细胞减少（25.0%）。未观察到与治疗相关的死亡。缓解率为50.0%（95%置信区间（CI）=21.5-78.5%）。基于S-1的化疗的中位无进展生存期（PFS）和总生存期（OS）分别为6.0个月和13.5个月。
发现基于S-1的化疗对复发TC患者可能有用。
